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THE ability of carnitine congeners to modulate cytokine
production by human peripheral blood mononuclear cells
(PBMC) was investigated. Modulation of cytokine
production byPBMC ofyoung (30 years ofage or younger)
and old (70 years of age or older) normal donors was first
compared. The PBMC were collected over Ficoll-Hypa-
que and incubated in the presence of various concentra-
tions of acetyl L-carnitine for 24 h. Subsequently the
supernatants were collected and examined for cytokine
production. The presence of cytokines in tissue culture
supernatants was examined by ELISA. The cytokines
measured included IL-10t, IL-1]], IL-2, IL-4, IL-6, TNF0t,
GM-CSF, and IFN/. The results showed that at 50 Itg/ml
of acetyl L-carnitine the most significant response was
obtained for TNF0t. In this regard four of five young
donors responded, but only one of five old donors
responded. More recently these studies were expanded to
examine the ability of L-carnitine to modulate cytokine
production at higher doses, 200 and 400 ltg/ml, in young
donors. The results of these studies showed that in
addition to TNF0t, significant production of IL-I and
IL-6 was observed. These preliminary studies provide
evidence that carnitine may modulate immune functions
through the production of selected cytokines.
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Introduction
Long-chain fatty acids are a major source for the
production of energy in humans. This is particularly
true for various organs including the liver, the
heart, and the skeletal muscle system. Energy is
generated through fl-oxidation of these fatty acids
which are transported by carnitine across the
mitochondrial membrane. In addition to its role
as a carrier for long-chain fatty acids, carnitine has
been implicated in other disorders. It has been
demonstrated that ]-,-carnitine O-palmitoyltrans-
ferase deficiency is accompanied by hypoketoic
hypoglycaemia and cardiomyopathy.
4 This observa-
tion may indicate a potential role for carnitine in
cardiac disease. Several reports have pointed to
the role of carnitine in the immune system. De
Simone and colleagues have noted that an increase
in carnitine concentration in the serum can
potentiate certain functions such as mixed lympho-
cyte reactions and chemotaxis, as well as increase
lymphocyte response to mitogens. Other studies
have also shown that treatment of carnitine depleted
post operative patients with i,-carnitine enhances
lymphocyte mitogenesis.
1 Improvement of im-
mune functions during stress or ageing upon
treatment with carnitine has also been well
documented.’2 Recent studies also showed that
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AIDS patients demonstrate a deficiency in L-
carnitine which may compromise their energy
supplies.
3 These observations provide evidence
that carnitine may be an important factor in the
normal function of the immune system.
In the present studies the effect of carnitine
congeners on the modulation of cytokine produc-
tion by human peripheral blood mononuclear
cells (PBMC) was examined. The results provide
evidence that acetyl i,-carnitine, and L-carnitine are
capable of inducing the production of selected
cytokines. Among the cytokines produced, IL-lfl
and IL-6 were produced. However, it was also
observed that significant concentrations of turnout
necrosis factor alpha (TNFz) were produced. The
measurement of TNFcz by ELISA was confirmed
by demonstrating the presence of messenger RNA
using the polymerase chain reaction (PCR)
technique.
Materials and Methods
Both acetyl L-carnitine and L-carnitine were a
generous gift from Sigma Tau, Pomezia, Rome,
Italy.
Peripheral blood cells: Peripheral blood was obtained
from normal donors by venous puncture, using
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heparinized vacutainer tubes (Becton-Dickinson,
San Jose, CA). Alternatively, when large numbers
of cells were needed, blood was obtained from the
Rhode Island Blood Center. The blood was
centrifuged over Ficoll-Hypaque gradients as has
been described previously. 14’1s The burly coat cells
at the interface of the gradient were collected and
washed to remove the Ficoll. The cells were then
resuspended in RPMI medium supplemented with
glutamine (200mM) and penicillin/streptomycin
(100 units/ml). These cells were then used for the
experiments as needed.
Production of cytokines: For cytokine production,
PBMC in supplemented RPMI medium were
adjusted to 1 x 106 cells/ml in supplemented RPMI
medium containing 2% heat inactivated foetal calf
serum (FCS).
16 Acetyl L-carnitine or I-carnitine
were added at various concentrations to cell
cultures. Cultures were incubated at 37C and 5%
CO2 in a humidified atmosphere for 24 h. Following
incubation, the supernatants were harvested and
filtered through a 0.2 #m filter (Gelman). The
supernatants were divided into aliquots and frozen
at -70C until needed. Control cultures included
cells incubated without carnitine, or cultures
incubated with 5/.tg/ml concancavalin A (Sigma).
Cytokine measurement: The presence of cytokines in
supernatant cultures was measured by using
enzyme linked immunosorbent assays (ELISA).
The kits for these assays were purchased from
Genzyme (Boston, MA) or R&D systems (Minnea-
polis, MN). All assays were performed in
accordance with the manufacturer’s instructions.
The washing steps were done using a plate washer
(ICN, Costa Mesa, CA) and the completed assays
were read on an MS2 plate reader (ICN) to which
an Okidata printer was attached. The concentra-
tions of the cytokines in the culture supernatants
were determined by reference to a set of standards
included in the ELISA kit.
Results and Discussion
The results of experiments comparing cytokine
production by acetyl-.-carnitine in young and old
normal individuals are summarized in Table 1. As
can be seen, at the maximum dose of 50 #g/ml of
acetyl t-carnitine used in these experiments, there
was significant production of TNF. The results
show that significant concentrations ofTNF were
produced by cells from four of five young donors,
but only one old donor showed significant
response. No measurable amounts of other
cytokines were observed in these initial experi-
ments. A graphic representation of this TNF
response is presented in Fig. 1. No or minimal
TNF0 < 10 pg/ml) was produced by cells cultured
Table 1. Modulation of cytokine production by acetyl
L-carnitine
Cytokine Young donors < 30 y Old donors > 70 y
GM-CSF 0/5 0/5
IFN- 0/5 0/5
TNF- 4/5 1/5
IL-1 0/5 0/5
IL-2 1/5 1/5
IL-4 0/5 0/5
IL-6 1/5 0/5
Human peripheral blood mononuclear cells (PBMC) were
incubated with or without acetyl L-carnitine at various doses
ranging from 0.01 to 50/g/ml, for 24 h. The supernatants were
collected and examined by ELISA for the presence of cytokines.
The results above are from cultures incubated with 50 /g/ml
acetyl L-carnitine
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FIG. 1. Induction of TNF= by acetyl L-carnitine, in peripheral blood cells
obtained from young (<30 years of age) and old (>70 years of age)
normal human donors. The maximum induction in this experiment post
24 h of incubation was about four times that of cells incubated without
acetyl L-carnitine. cells alone; cells + acetyl-L-carnitine. Cells
incubated with concanavalin A were used as a positive control producing
approximately 700 pg/ml. Cytokine measurement was done by ELISA.
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FIG. 2. Induction of IL-lfl, but not IL-I in peripheral blood of normal
human cells, following incubation for 24 h in the presence of L-carnitine.
Cells incubated with concanavalin A were used as a positive control.
IL-1/Y levels increased from 4pg/ml for cells without L-carnitine to
45 pg/ml and 100 pg/ml when cells were incubated with 200 and
400 #g/ml of L-carnitine, respectively. Cytokine measurement was done
by ELISA.., cells alone; 11, cells+L-carnitine (200#g/ml);],
cells+L-carnitine (400 #g/ml); [], cells+Con A.
in the absence of acetyl L-carnitine, which when
added at 50/g/ml induced significant concentra-
tions of the cytokine, in some donors being as high
as five times that of unstimulated cells. These results
provide evidence that acetyl L-carnitine can
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FIG. 3. Induction of IL-6 by normal human peripheral blood cells
incubated with L-carnitine. L-6 levels rose from virtually 0 pg/ml for ceils
without L-carnitine to 150 and 400 pg/ml in the presence of 200 and
400/g/ml L-carnitine, when incubated for 24 h. Similar results were
obtained for TNF with these concentrations of L-carnitine. TNF levels
increased from virtually 0 pg/ml to 110 and 234 pg/ml, respectively. I,
cells alone; II, cells+L-carnitine (200#g/ml); Ii cells+L-carnitine
(400 #g/ml); r, cells+ Con A.
modulate the production of cytokines by human
PBMC. It appears however, that this process of
cytokine production is more pronounced in cells of
young donors than in cells obtained from old
donors. This observation needs to be confirmed by
Table 2. Modulation of cytokine production by L-carnitine
Supernatant TNF L-6 L- 1/t L-
Cells alone 5 pg/ml < 10 pg/ml 4 pg/ml < 5 pg/ml
Cells + L-car 200 10 pg/ml 150 pg/ml 101 pg/ml <5 pg/ml
Cells + L-car 400 234 pg/ml 400 pg/ml 151 pg/ml < 5 pg/ml
Cells + Con A 685 pg/ml 1800 pg/ml 354 pg/ml 100 pg/ml
Human peripheral blood mononuclear cells were incubated with or without L-carnitine (at
200 and 400 #g/ml) for 24 h. The supernatants were harvested and examined by ELISA
for the presence of cytokines. Cells with concanavalin A (5 #g/ml) were included as
a positive control
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using larger numbers of donors, before a conclusion
can be made.
The above experiments were extended in young
donors using L-carnitine instead of acetyl I-
carnitine. In addition, the concentrations of
I-carnitine used were higher than those used for
acetyl L-carnitine, being 200 and 400 #g/ml. Figure
2 shows the results for one of at least three separate
experiments for IL-10q and IL-lfl, all of which gave
similar results. It is clear from the data that IL-lfl
but not IL-1 is produced in the presence of
-carnitine. The data for these experiments are
summarized in’-Table 2. Similar results were
obtained for IL-6 and for TNF which can be seen
in Fig. 3. Of importance in these experiments is that
the concentrations of the cytokines increased in
response to increased concentrations of L-carnitine
(Table 2). Of the cytokines measured to date it
appears that the induction of TNF is observed at
concentrations of carnitine which are not inductive
for other cytokines. Thus at 50/.tg/ml of acetyl
-carnitine there was strong induction ofTNF but
not other cytokines. It should be mentioned,
however, that oral administration of acetyl
-carnitine did not result in significant modifications
of TNF0 levels. 17 In the present study, the small
number of donors has to be taken into considera-
tion before conclusions can be drawn. Nevertheless,
one also has to consider that this selection for TNF0
production may be associated with some unique
features of the ability of carnitine to modulate the
immune response.
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